Guosen Securities (HK)  
Skip Navigation Links

()
分析师 建议 目标股价 上升/下降(%)
总市值(十亿/十亿美元) 日均成交额(百万美元) 收盘 52周最高/最低()
/ -
+ 财务摘要 点击图标下载Excel版本
 
- 损益表 点击图标下载Excel版本
 
- 资产负债表 点击图标下载Excel版本
 
- 财务比率 点击图标下载Excel版本
 
- 杜邦分析 点击图标下载Excel版本
 
- 现金流 点击图标下载Excel版本
 
股票数据
 一天一周一个月三个月六个月一年从月初从年初
绝对回报 (%) (1.55) (4.29) 2.86 15.52 51.84 89.02 0 45.42
绝对回报 (美元, %) (1.55) (4.29) 2.86 15.53 N.A. 91.22 N.A. 46.20
相对于 HSI 回报 (%) 0.27 (0.06) 11.63 21.46 N.A. 100.32 7.41 62.73
 
最新五个研究报告
下面包含5个最新的研究报告,请到研究报告存库页面检索所有相关文件。
 
联邦制药 (3933 HK) 销售额及利润率继续回升 - 9月 11, 2018 (8 页)  
联邦制药8月29日公布其2018年中期净利润为人民币9100万元,核心利润为人民币3.99亿元(17年中期:人民币6800万元),超出我们18财年预期并占分析师一致预期的71%,归因于更高的6-APA与原料药价格及更大的利润率。我们预计2018年(1)二代胰岛素销量将达1500万支(17财年:1300万);及(2)甘精胰岛素销售额将达人民币5500万元(17财年:人民币4600万元)。我们维持买入评级,而基于对现金流折现法估值加回净债务部分及更高的WACC假设,下调分部总和目标价至10.10港元。

Healthy 2018 insulin outlook - 4月 3, 2018 (9 页)  
United Lab, on 28 Mar, released its FY17 earnings at RMB82m, while core profit of RMB263m beat ours of RMB117m but below consensus (FY16: -RMB60m). Post briefing, we see, in 2018, (1) 6-APA prices to stay high at RMB210-230/ton (FY17: RMB200/t); (2) 2nd gen insulin sales at 15m vials (FY17: 13m); and (3) Glargin sales to double from 2017. If all 3rd gen insulin starts sales, our TP will offer 77% upside vs current price. Keep BUY with lower TP of HKD11.00 on higher WACC.

China Healthcare Focus on biotech and high-end drugmakers - 3月 14, 2018 (18 页)  
In the upcoming (Dec-ended) result season and from those stocks we actively cover, we expect biotech (Genscript) and high-end drugmakers (3SBio and Livzon Pharm) to have in-line results with Bloomberg consensus and ours. Moreover, concentrated Chinese medicine granule (CCMG) leader (China TCM) is forecast to beat consensus, on recovering finished drug and stable CCMG sales and margins. We see drug-makers like United Lab, Luye and Sinopharm as the key distributor would likely fall short of consensus estimate.

The United Lab (3933 HK) 113% TP upside post 3rd gen insulin approvals - 2月 9, 2018 (13 页)  
United Lab (UL) announced its insulin aspart (门冬胰岛素) application for production permit had been accepted by CFDA on 15 Nov 2017. We expect it to start sales in mid-2019. Albeit of our FY17F-19F earnings cut on bigger production cost, we add the R&D valuation for all insulin sales, lifting our TP to HKD11.20. Should all 3rd gen insulin start sales, our TP will offer 113% upside vs current price. Keep BUY.

The United Lab (3933 HK) Good upstream pricing sustainable - 8月 28, 2017 (8 页)  
On 24 Aug, United Lab (UL) reported its 1H17 earnings at RMB109m. Without one-off items, it reduced to RMB68m (ours: RMB32m), but turned around from 1H16’s net loss of RMB23m. Post Management update, in 2017, we see (1) 6-APA pricing to sustain high at over RMB185/ton; (2) 2nd gen insulin sales to 13m vials (1H17: 4.4m) down from previous 15m; (3) Glargin to have RMB21m sales. Keep BUY with higher SOTP-TP at HKD9.60 on bigger sales and smaller opex to sales.


CopyRight © 2009-2015 国信证券(香港)经纪有限公司版权所有